Molecular targets of atypical antipsychotics: From mechanism of action to clinical differences

S Aringhieri, M Carli, S Kolachalam, V Verdesca… - Pharmacology & …, 2018 - Elsevier
The introduction of atypical antipsychotics (AAPs) since the discovery of its prototypical drug
clozapine has been a revolutionary pharmacological step for treating psychotic patients as …

Tricyclic antidepressant pharmacology and therapeutic drug interactions updated

PK Gillman - British journal of pharmacology, 2007 - Wiley Online Library
New data on the pharmacology of tricyclic antidepressants (TCAs), their affinities for human
cloned CNS receptors and their cytochrome P450 enzyme inhibition profiles, allow improved …

The neurobiology and control of anxious states

MJ Millan - Progress in neurobiology, 2003 - Elsevier
Fear is an adaptive component of the acute “stress” response to potentially-dangerous
(external and internal) stimuli which threaten to perturb homeostasis. However, when …

Psychedelics as transformative therapeutics

BL Roth, RH Gumpper - American Journal of Psychiatry, 2023 - Am Psychiatric Assoc
Over the past decade, psychedelic compounds have emerged as potentially transformative
therapeutics for a variety of intractable neuropsychiatric conditions. However, historically …

The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical …

MJ Millan, A Gobert, F Lejeune, A Dekeyne… - … of Pharmacology and …, 2003 - ASPET
Agomelatine (S20098) displayed p K i values of 6.4 and 6.2 at native (porcine) and cloned,
human (h) 5-hydroxytryptamine (5-HT) 2C receptors, respectively. It also interacted with h5 …

Multi-target strategies for the improved treatment of depressive states: conceptual foundations and neuronal substrates, drug discovery and therapeutic application

MJ Millan - Pharmacology & therapeutics, 2006 - Elsevier
Major depression is a debilitating and recurrent disorder with a substantial lifetime risk and a
high social cost. Depressed patients generally display co-morbid symptoms, and depression …

Antidepressants and sleep: a qualitative review of the literature

S Wilson, S Argyropoulos - Drugs, 2005 - Springer
Most antidepressants change sleep; in particular, they alter the physiological patterns of
sleep stages recorded overnight with EEG and other physiological measures. These effects …

Serotonergic modulation of the activity of mesencephalic dopaminergic systems: therapeutic implications

P De Deurwaerdère, G Di Giovanni - Progress in neurobiology, 2017 - Elsevier
Since their discovery in the mammalian brain, it has been apparent that serotonin (5-HT)
and dopamine (DA) interactions play a key role in normal and abnormal behavior …

Synergistic action of 5-HT2A antagonists and selective serotonin reuptake inhibitors in neuropsychiatric disorders

GJ Marek, LL Carpenter, CJ McDougle… - …, 2003 - nature.com
Recently, the addition of drugs with prominent 5-HT 2 receptor antagonist properties
(risperidone, olanzapine, mirtazapine, and mianserin) to selective serotonin reuptake …

Serotonin 5-HT2C receptors as a target for the treatment of depressive and anxious states: focus on novel therapeutic strategies

MJ Millan - Therapies, 2005 - Elsevier
Abstract Serotonin (5-HT) 2C receptors play an important role in the modulation of
monoaminergic transmission, mood, motor behaviour, appetite and endocrine secretion …